Social posts cite Wegovy weight-loss numbers
- Hims & Hers and X users posted semaglutide weight-loss claims on May 14 and May 15, 2026, mixing company pricing messages with anecdotal results. - Hims & Hers says its weight-loss membership renews at $149 a month after month one, while company materials cite approved treatments that can help users lose up to 20%. - Hims & Hers lists Wegovy pill and pen options on its weight-loss pages, where membership pricing and medication terms are posted.
Social media posts over the last two days circulated eye-catching semaglutide numbers tied to Wegovy and Hims & Hers, including one claim of “27.7% weight loss (84% fat)” and another about a $149 monthly fee. The posts mixed different kinds of information: individual self-reported outcomes, company marketing language and published trial data. Hims & Hers does sell access to FDA-approved semaglutide products through its platform, but its own materials describe the $149 figure as a membership charge, not a stand-alone drug price. Company pages and clinical sources also show lower, trial-based weight-loss figures than the social posts implied. ### Where did the $149 figure come from? Hims & Hers says on its weight-loss FAQ and Wegovy product pages that customers pay $39 for the first month of the weight-loss membership and $149 a month after that, with medication billed separately if prescribed. The company repeats the same structure on its main weight-loss page, which says the membership fee is “not included” in listed medication prices. March 26 company materials tied that membership launch to a broader rollout of Novo Nordisk’s FDA-approved GLP-1 medicines on the platform. (hims.com) Hims & Hers said at the time that Wegovy pill and Wegovy pen options would be available to eligible customers and that prices for medications start as low as $149 a month, while membership costs remain separate. ### Did Hims & Hers recently change its semaglutide business? Hims & Hers said in March 2026 that it was making a “strategic shift” in its U.S. weight-loss business as it aligned more of its offering around approved medications. Separate company announcements in March said the platform would offer Wegovy pills and injections and Ozempic injections through its collaboration with Novo Nordisk. (investors.hims.com) May 2024 company announcements had centered on compounded GLP-1 injections starting at $199 a month during the period of industry shortages. The newer Hims & Hers pages emphasize FDA-approved products, including Wegovy, and pair them with the membership model that renews at $149 a month. ### What about the “27.7% weight loss” claim? (investors.hims.com) Hims & Hers’ March 18 product post cited a 71-week double-blind, placebo-controlled trial of oral semaglutide 25 mg in adults with overweight or obesity. That post said 27.9% of participants lost at least 20% of body weight by week 64, while average weight loss in the treatment group was 13.6% versus 2.4% for placebo. (news.hims.com) The distinction matters because 27.9% in that material refers to the share of participants who crossed a threshold, not the average percentage of body weight lost. A separate pivotal trial of once-weekly semaglutide 2.4 mg injection reported mean weight loss of 14.9% at week 68, according to the New England Journal of Medicine. ### Is “84% fat” a published clinical result? The “84% fat” figure could not be verified in Hims & Hers’ product pages, investor materials or the clinical sources reviewed here. (news.hims.com) The company’s March 18 and March 26 materials cite body-weight outcomes and threshold-based responder data, but not an 84% body-fat composition result. (nejm.org) FDA labeling for Wegovy also frames efficacy around weight reduction and safety information, not the kind of body-composition statistic highlighted in the social post. The label says Wegovy contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonists. ### What can readers verify right now? Hims & Hers’ current weight-loss pages list Wegovy pill from $149 a month and Wegovy pen from $199 a month, with the membership fee billed separately. (investors.hims.com) The company’s FAQ says the membership renews at $149 monthly after the first month, and its March 26 release says eligible customers can access approved semaglutide options through the platform. Readers can compare those posted terms with the company’s FAQ, product pages and investor release dated March 26, 2026. (accessdata.fda.gov) (hims.com)
